Q3 2026 TU
Logotype for Sandoz Group AG

Sandoz (SDZ) Q3 2026 TU earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Sandoz Group AG

Q3 2026 TU earnings summary

28 Oct, 2026

Executive summary

  • Q3 net sales were USD 2.942bn, up 5% at constant currencies (CC), or 7% excluding the anti-infective B2B impact; the 20th consecutive quarter of net sales growth.

  • Biosimilars grew 17% at CC and reached 34% of Q3 sales; strong volume demand offset price headwinds.

Financial highlights

  • 9M net sales were USD 8.703bn, up 8% in USD and 5% at CC; underlying CC growth was 6% excluding the anti-infective B2B impact.

  • 9M volume growth was 10%, partly offset by 5% price erosion; FX contributed USD 0.2bn against a USD 0.4bn price impact.

  • Q3 biosimilar sales grew 17% at CC to USD 998m; generics were flat, or up 2% excluding the anti-infective B2B impact.

Outlook and guidance

  • FY26 net-sales growth guidance narrowed to 5%-6% at CC from mid-to-high single digits; Q4 growth is expected to step up versus Q3.

  • Core EBITDA margin guidance rose to 23.0%-23.5%, versus 21.7% in 2025; core EPS expectations also increased.

  • Assumptions include mid-single-digit price erosion, no material generic semaglutide sales contribution in 2026, and a +2 percentage-point spot-FX impact on sales with no material margin impact.

  • Long-term targets include mid-to-high-single-digit net-sales CAGR at CC for 2025-2030, core EBITDA margin of 25%-27% by 2030, and more than doubling 2035 net sales versus 2025 with margin above 30%, excluding GLP-1 upside.

  • Bio100 targets 100+ biosimilars by 2040; management expressed confidence in 2027 and supports consensus growth of ~5.5% at comparable currencies but has not issued FY27 guidance.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Sandoz